Navigation Links
Pinnacle Biologics Announces Logistics Services Agreement With the Movianto Group
Date:6/16/2008

ROCKVILLE, Md., June 17 /PRNewswire/ -- Pinnacle Biologics, a private, full-service pharmaceutical and biotech solutions company, today announced it has entered into a logistic service agreement with Movianto, a German-based company. The agreement, which is scheduled to take effect immediately, grants Movianto certain logistics and distribution rights in several countries in Europe. Additional terms of the agreement were not disclosed.

"The agreement with Movianto represents another milestone in Pinnacle's infrastructure and further showcases our vast capability to assist large pharmaceutical and biotechnology companies in optimizing the international market potential of mature products without diversion of resources from core businesses," said Guillermo Herrera, chairman of the board of Pinnacle Biologics. "Additionally, the Pinnacle business model is optimal for small biotechnology that require a total solution from pre-launch to commercialization of products."

Conor Roche, managing director of the Movianto Group commented: "Movianto is extremely excited about expanding our service portfolio to meet Pinnacle's unique distribution and logistics requirements and to accelerate the commercialization of the Pinnacle business model in Europe."

About Pinnacle Biologics

Founded in 2007 by health care executives Guillermo Herrera, James Miller, and Viren Grover, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.

Pinnacle provides a full range of services including regulatory, sales, marketing, distribution (including billing and collections), pharmacovigilence, product safety, market research and administrative services.

About Movianto

Movianto provides the pharmaceutical, biotechnology and healthcare industry with innovative logistics and distribution solutions across Europe. Movianto's 400 international clients, including the world's ten largest pharmaceutical manufacturers, benefit from a broad range of pharmaceutical logistics services and the variety of distribution models at national, regional and European level. Movianto is a business unit of Celesio AG. For further information, please visit http://www.movianto.com


'/>"/>
SOURCE Pinnacle Biologics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
2. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
7. MedImmune Submits Biologics License Application to FDA for Motavizumab
8. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
9. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
10. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
11. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... The BMT Tandem ... Center for International Blood & Marrow Transplant Research (CIBMTR) will take place Feb. ... , The combined scientific sessions offer investigators, clinicians, laboratory technicians, clinical research professionals, ...
(Date:2/17/2017)... According to a new ... Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, ... Development, Disease-Risk) - Global Forecast to 2021" published ... USD 53.34 Billion by 2021 from USD 27.95 ... 13.8% during the forecast period (2016-2021). ...
(Date:2/17/2017)... ... February 17, 2017 , ... Academy of Model ... world’s leading maker of unmanned aircraft systems (UAS), are launching a joint program ... drones effectively, and support educational outreach efforts. , AMA and DJI will collaborate ...
(Date:2/16/2017)... ... February 16, 2017 , ... Avomeen & MichBio will be hosting a BioMixer ... at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan 48108). BioMixers are ... opportunity to interact with peers, make new connections and talk bio biz. , Cost:, ...
Breaking Biology Technology:
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to ... and meaningful advances worldwide, The Japan Prize Foundation ... Prize, who have pushed the envelope in their ... and Communication. Three scientists are being recognized with ... achievements that not only contribute to the advancement ...
(Date:1/26/2017)... 26, 2017  Acuity Market Intelligence today released ... Digital Identity".  Acuity characterizes 2017 as a "breakout" ... adoption reflects a new understanding of the potential ... and digital identity are often perceived as threats ... , Principal of Acuity Market intelligence. "However, taken ...
Breaking Biology News(10 mins):